FIELD: medicine.
SUBSTANCE: invention relates to an anti-tumour agent which is a ready dosage form in the form of a lyophilizate for parenteral administration for targeted delivery of particles into the affected organs and tissues, as well as for prolonged action. Anti-tumour agent contains an alpha-hydroxybenzole propane acid derivative, a lactic and glycolic acid copolymer, an alpha-fetoprotein functional fragment and a cryoprotector.
EFFECT: invention provides higher effectiveness of the anti-tumour agent.
3 cl, 3 dwg, 2 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONJUGATE OF ANTITUMOUR DRUGS WITH RECOMBINANT ALPHA-FETOPROTEIN AND ITS FUNCTIONAL FRAGMENTS AND METHOD OF THEIR PRODUCING | 2016 |
|
RU2630974C1 |
| ANTITUMOR PEPTIDE PREPARATION BASED ON ALPHA-FETOPROTEIN FRAGMENT, ITS CONJUGATE, PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATMENT OF HORMONE-DEPENDENT TUMORS | 2005 |
|
RU2285537C1 |
| ANTI-TUMOUR PREPARATION | 2011 |
|
RU2451509C1 |
| METHOD FOR PRODUCING ACTIVE FRAGMENT OF HUMAN ALPHA-FETOPROTEIN | 2010 |
|
RU2448116C2 |
| DIAGNOSTICS AND TREATMENT OF CANCER ASSOCIATED WITH CANCER STEM CELLS | 2014 |
|
RU2749867C2 |
| METHOD FOR TREATMENT OF MALIGNANT NEOPLASM, USING COMBINATION OF ANTIBODY TO PD-1 AND CHEMOTHERAPEUTIC AGENT | 2021 |
|
RU2787457C2 |
| THERAPY OF METASTATIC UROTHELIAL CANCER USING ANTIBODY-DRUG CONJUGATE SATSITUZUMAB GOVITECAN (IMMU-132) | 2017 |
|
RU2757395C2 |
| METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO COMPONENTS OF THE SIGNAL PATH PD-1, AND TAXANES | 2014 |
|
RU2719487C2 |
| TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER CHARACTERIZED BY Trop-2 EXPRESSION USING SATSITUZUMAB GOVITECAN AND Rad51 INHIBITOR | 2018 |
|
RU2758234C2 |
| THERAPEUTIC COMBINATIONS CONTAINING ANTI-FOLR1 IMMUNOCONJUGATES | 2016 |
|
RU2749865C2 |
